ATE226949T1 - Verfahren zur herstellung von tolterodin - Google Patents

Verfahren zur herstellung von tolterodin

Info

Publication number
ATE226949T1
ATE226949T1 AT97954678T AT97954678T ATE226949T1 AT E226949 T1 ATE226949 T1 AT E226949T1 AT 97954678 T AT97954678 T AT 97954678T AT 97954678 T AT97954678 T AT 97954678T AT E226949 T1 ATE226949 T1 AT E226949T1
Authority
AT
Austria
Prior art keywords
tolterodine
producing
producing tolterodine
benzopyran
dihydro
Prior art date
Application number
AT97954678T
Other languages
English (en)
Inventor
James R Gage
John E Cabaj
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Application granted granted Critical
Publication of ATE226949T1 publication Critical patent/ATE226949T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/20—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 hydrogenated in the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/02—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
AT97954678T 1996-12-31 1997-12-18 Verfahren zur herstellung von tolterodin ATE226949T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3396196P 1996-12-31 1996-12-31
PCT/US1997/022521 WO1998029402A1 (en) 1996-12-31 1997-12-18 Process to prepare tolterodine

Publications (1)

Publication Number Publication Date
ATE226949T1 true ATE226949T1 (de) 2002-11-15

Family

ID=21873473

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97954678T ATE226949T1 (de) 1996-12-31 1997-12-18 Verfahren zur herstellung von tolterodin

Country Status (23)

Country Link
US (1) US5922914A (de)
EP (1) EP0960109B1 (de)
JP (1) JP4199310B2 (de)
KR (2) KR20000057548A (de)
CN (1) CN1151141C (de)
AT (1) ATE226949T1 (de)
AU (1) AU717985B2 (de)
CA (1) CA2273789C (de)
CZ (1) CZ295477B6 (de)
DE (1) DE69716767T2 (de)
DK (1) DK0960109T3 (de)
ES (1) ES2186018T3 (de)
FI (1) FI991477A0 (de)
HK (1) HK1023566A1 (de)
HU (1) HUP0000527A3 (de)
NO (1) NO317158B1 (de)
NZ (1) NZ336533A (de)
PL (1) PL191603B1 (de)
PT (1) PT960109E (de)
RU (1) RU2176246C2 (de)
SI (1) SI0960109T1 (de)
SK (1) SK283591B6 (de)
WO (1) WO1998029402A1 (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000515525A (ja) * 1996-07-19 2000-11-21 アベーグ，グンナー 尿と胃腸の疾患の治療におけるｓ（―）―トルテロジン
EP0957073A1 (de) * 1998-05-12 1999-11-17 Schwarz Pharma Ag 3,3-Diphenylpropylaminderivate
DE60020613T2 (de) * 1999-07-01 2006-03-16 Pharmacia & Upjohn Co. Llc, Kalamazoo (S,S)-Reboxetin zur Behandlung von Fibromyalgie und anderen somatoformen Störungen
US6566537B2 (en) 1999-12-30 2003-05-20 Pharmacia Ab Process and intermediates
SE9904850D0 (sv) * 1999-12-30 1999-12-30 Pharmacia & Upjohn Ab Novel process and intermediates
DE10028443C1 (de) * 2000-06-14 2002-05-29 Sanol Arznei Schwarz Gmbh Verfahren zur Herstellung von 3,3-Diarylpropylaminen, (R,S)- und (R)-4-Phenyl-2-chromanon-6-carbonsäure sowie (R)-4-Phenyl-2-chromanon-carbonsäure-cinchonidinsalz und deren Verwendung zur Herstellung eines rechtsdrehenden Hydroxybenzylalkohols und von pharmazeutischen Zusammensetzungen
DE10033016A1 (de) * 2000-07-07 2002-01-24 Sanol Arznei Schwarz Gmbh Verfahren zur Herstellung von 3,3-Diarylpropylaminen
PE20020547A1 (es) 2000-10-24 2002-06-12 Upjohn Co Uso de la tolterodina en tratamientos del asma
US20030027856A1 (en) * 2001-06-29 2003-02-06 Aberg A.K. Gunnar Tolterodine metabolites
IN191835B (de) * 2001-08-03 2004-01-10 Ranbaxy Lab Ltd
MXPA04003865A (es) * 2001-10-26 2004-07-08 Upjohn Co Compuestos de amonio cuaternario y sus usos como agentes antimuscarinicos.
US7005449B2 (en) * 2002-04-23 2006-02-28 Pharmacia & Upjohn Company Tolterodine salts
EP1546099B1 (de) 2002-07-08 2008-12-31 Ranbaxy Laboratories Limited 3,6-disubstituierte azabicyclo-3.1.0 hexan-derivate als muscarinische rezeptorantagonisten
EP1546098B1 (de) 2002-07-31 2008-05-28 Ranbaxy Laboratories Limited 3,6-disubstituierte azabicyclo [3.1.0]hexanderivate, die sich als muscarinrezeptorantagonisten eignen
US7410993B2 (en) 2002-08-09 2008-08-12 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0] hexane deriviatives useful as muscarinic receptor antagonists
US7288562B2 (en) 2002-08-23 2007-10-30 Ranbaxy Laboratories Limited Fluoro and sulphonylamino containing 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives as muscarinic receptor antagonists
WO2004019925A1 (en) * 2002-08-28 2004-03-11 Pharmacia Corporation Oral liquid tolterodine composition
US7232835B2 (en) 2002-12-10 2007-06-19 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo derivatives as muscarinic receptor antagonists
AU2002347552A1 (en) 2002-12-23 2004-07-14 Ranbaxy Laboratories Limited 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
EP1581522B1 (de) 2002-12-23 2008-02-20 Ranbaxy Laboratories Limited Flavaxat-derivate als muscarin-rezeptor antagonisten
US7488748B2 (en) 2003-01-28 2009-02-10 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
WO2004078700A1 (en) * 2003-03-06 2004-09-16 Ranbaxy Laboratories Limited 3,3-diarylpropylamine derivatives and processes for isolation thereof
US7393874B2 (en) * 2003-04-08 2008-07-01 Hetero Drugs Limited Polymorphs of tolterodine tartrate
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
AU2003214520A1 (en) 2003-04-09 2004-11-01 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
US7560479B2 (en) 2003-04-10 2009-07-14 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
US7592359B2 (en) 2003-04-10 2009-09-22 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
EA009387B1 (ru) 2003-04-11 2007-12-28 Рэнбакси Лабораториз Лимитед Азабициклические производные в качестве антагонистов мускаринового рецептора
ITMI20031354A1 (it) * 2003-07-02 2005-01-03 Istituto Di Chimica Biomolecolare D El Cnr Sezione Sintesis enantioselettiva di composti enantiomericamente arricchiti.
ES2235648B1 (es) * 2003-12-22 2006-11-01 Ragactives, S.L. Procedimiento para la obtencion de tolterodina.
CA2551501C (en) * 2003-12-24 2012-05-29 Cipla Limited Tolterodine, compositions and uses thereof, and preparation of the same
EP1629834A1 (de) 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Pharmazeutische Zusammensetzung von Tolterodin mit verzögerter Freisetzung
ITMI20041920A1 (it) * 2004-10-11 2005-01-11 Chemi Spa Processo per la preparazione di n, n-diisopropil-3-2-idrossi-5-metilfenil-3-fenil-propabammina
US7355077B2 (en) * 2004-10-28 2008-04-08 Dr. Reddy's Laboratories Limited Process for preparing tolterodine
JP4513535B2 (ja) * 2004-12-03 2010-07-28 住友化学株式会社 トルテロジンの製造方法
TW200637804A (en) * 2005-01-10 2006-11-01 Teva Pharma Substantially pure tolterodine tartrate and process for preparing thereof
US7528267B2 (en) * 2005-08-01 2009-05-05 Girindus America, Inc. Method for enantioselective hydrogenation of chromenes
ES2268987B1 (es) 2005-08-05 2008-02-01 Ragactives, S.L. Procedimiento para la obtencion de 3,3-difenilpropilaminas.
WO2007039918A1 (en) * 2005-10-06 2007-04-12 Natco Pharma Limited Novel process for the preparation of tolterodine
WO2007045979A1 (en) 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of muscarinic receptor antagonists
KR100686351B1 (ko) * 2006-01-12 2007-02-22 주식회사 카이로제닉스 톨테로딘 라세미체의 제조방법
ITMI20060110A1 (it) * 2006-01-24 2007-07-25 Dipharma Spa Procedimento per la purificazione di tolterodina
CN101454304B (zh) 2006-05-24 2012-05-30 辉瑞有限公司 用于制造苯并吡喃-2-醇衍生物的方法
US7268257B1 (en) 2006-05-31 2007-09-11 Sumitomo Chemical Company, Limited Process for producing tolterodine
CZ302585B6 (cs) * 2007-02-26 2011-07-20 Zentiva, A. S. Krystalická sul 2-[(1R)-3-[bis(1-methylethyl)amino]-1-fenylpropyl]-4-methylfenolu s kyselinou (2R,3R)-2,3-dihydroxybutandiovou
US8486452B2 (en) * 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
US8871275B2 (en) 2007-08-08 2014-10-28 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
KR101188333B1 (ko) 2008-02-20 2012-10-09 에스케이케미칼주식회사 안정성이 우수하고 경피제로 유용한 톨테로딘 결정성산부가염
US20090214665A1 (en) * 2008-02-26 2009-08-27 Lai Felix S Controlled Release Muscarinic Receptor Antagonist Formulation
ITMI20082055A1 (it) * 2008-11-19 2009-02-18 Dipharma Francis Srl Procedimento per la preparazione di (r)-tolterodina base libera
WO2010092500A2 (en) 2009-02-12 2010-08-19 Alembic Limited A process for the preparation of tolterodine tartrate
WO2010094292A1 (en) * 2009-02-17 2010-08-26 Pharmathen S.A. Improved process for the preparation of (r)-2-(3-diisopropylamino)-1-phenylpropyl)-4methylphenol and salts thereof
WO2011125763A1 (ja) 2010-03-31 2011-10-13 小野薬品工業株式会社 手足症候群の予防および／または治療剤
WO2012098044A1 (en) 2011-01-17 2012-07-26 Cambrex Profarmaco Milano S.R.L. Process for the preparation of n,n-diisopropyl-3-(2-hydroxy-5-methylphenyl)- 3-phenyl propylamine and its salts starting from a novel intermediate
EP2476665A1 (de) 2011-01-17 2012-07-18 Cambrex Profarmaco Milano S.r.l. Verfahren zur Herstellung von N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)- 3-phenyl-Propylamin und seine Salze aus einem neuartigen Zwischenstoffs
CN102516098B (zh) * 2011-12-09 2014-06-18 北京联本医药化学技术有限公司 酒石酸托特罗定制备方法
CN103044274B (zh) * 2012-11-29 2014-10-22 珠海保税区丽珠合成制药有限公司 一种无溶剂合成酒石酸托特罗定的方法
GB201402556D0 (en) 2014-02-13 2014-04-02 Crystec Ltd Improvements relating to inhalable particles
CN110229072B (zh) * 2019-06-25 2022-04-08 中国药科大学 一种托特罗定及其对映体的合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8800207D0 (sv) * 1988-01-22 1988-01-22 Kabivitrum Ab Nya aminer, deras anvendning och framstellning
US5382600A (en) * 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
NO179904C (no) * 1992-09-04 1997-01-08 Takeda Chemical Industries Ltd Kondenserte heterocykliske forbindelser og deres anvendelse

Also Published As

Publication number Publication date
PL334375A1 (en) 2000-02-28
NO993247D0 (no) 1999-06-29
SK283591B6 (sk) 2003-10-07
CN1238768A (zh) 1999-12-15
FI991477A (fi) 1999-06-29
FI991477A0 (fi) 1999-06-29
JP2001507691A (ja) 2001-06-12
SI0960109T1 (en) 2003-04-30
US5922914A (en) 1999-07-13
EP0960109B1 (de) 2002-10-30
CZ295477B6 (cs) 2005-08-17
DE69716767D1 (de) 2002-12-05
AU5956998A (en) 1998-07-31
PT960109E (pt) 2003-03-31
KR100463614B1 (ko) 2004-12-29
CZ227299A3 (cs) 1999-11-17
CN1151141C (zh) 2004-05-26
CA2273789C (en) 2006-06-06
WO1998029402A1 (en) 1998-07-09
RU2176246C2 (ru) 2001-11-27
HUP0000527A2 (hu) 2001-11-28
SK81599A3 (en) 1999-12-10
DE69716767T2 (de) 2003-06-12
ES2186018T3 (es) 2003-05-01
JP4199310B2 (ja) 2008-12-17
AU717985B2 (en) 2000-04-06
KR20000057548A (ko) 2000-09-25
NO317158B1 (no) 2004-08-30
CA2273789A1 (en) 1998-07-09
EP0960109A1 (de) 1999-12-01
DK0960109T3 (da) 2002-11-25
NZ336533A (en) 2000-05-26
PL191603B1 (pl) 2006-06-30
HK1023566A1 (en) 2000-09-15
HUP0000527A3 (en) 2001-12-28
KR20000069771A (ko) 2000-11-25
NO993247L (no) 1999-08-09

Similar Documents

Publication Publication Date Title
ATE226949T1 (de) Verfahren zur herstellung von tolterodin
DE69620461D1 (de) Verfahren zur herstellung von 1,1,1,3,3,-pentafluoropropanen
DE69623460T2 (de) Verfahren zur herstellung von 3-haloalkyl-1h-pyrazole
ATE326476T1 (de) Verfahren zur herstellung von phosphorothioat- oligomeren
ATE241012T1 (de) Verfahren zur herstellung von humanen relaxin
DE69618476T2 (de) Verfahren zur herstellung von 1,1,1,3,3-pentafluorpropan
DE69512250T2 (de) Verfahren zur herstellung von 1,1,1,3,3,3- hexafluorpropan
DE59602230D1 (de) Verfahren zur Herstellung von 2,2-Difluorbenzo[1.3]dioxolcarbaldehyden
DE59007171D1 (de) Verfahren zur herstellung von sclareolid.
DE3771657D1 (de) Verfahren zur herstellung von cyclopentanon.
ATA41091A (de) Verfahren zur herstellung von beta-(d)-2',3'-didesoxyinosin
DE59001106D1 (de) Verfahren zur herstellung von 1,1,1-trifluor-2-chlorethan.
DE69603261D1 (de) Verfahren zur herstellung von 1,2-benzisothiazolonen
ATE187959T1 (de) Lösungsmittelfreies verfahren zur herstellung von 2,6 difluorbenzonitril
DE69631154D1 (de) Verfahren zur herstellung von 1,1,1,3,3-pentafluorpropan
DE3779247D1 (de) Verfahren zur herstellung von 2,3,5-trimethylhydrochinon.
DE68916022D1 (de) Verfahren zur herstellung von wasserstoffgas.
DE69002134D1 (de) Verfahren zur herstellung von 1,1-dichlor-1-fluoroethan und 1-chlor-1-1-difluorethan.
ATE211716T1 (de) Verfahren zur herstellung von feinverteiltes metallisches kobalt enthaltendem kobalt(ii)-oxid
DE3770059D1 (de) Verfahren zur herstellung von 4,4'-bis-phenol.
ATE269863T1 (de) Verfahren zur herstellung von granisetron
DE69012103T2 (de) Verfahren zur herstellung von 4,4'-diisopropylbiphenyl.
DE59002140D1 (de) Verfahren zur herstellung von 2,3,5-trimethyl-p-benzochinon.
DE68916805T2 (de) Verfahren zur herstellung von tocopherolen.
DE3767843D1 (de) Verfahren zur herstellung von 2-brom-1',2'-dichloroperfluordiethylether.